Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Desocort
2. Desone
3. Desowen
4. Locapred
5. Locatop
6. Prednacinolone
7. Tridsonit
8. Tridesilon
1. 638-94-8
2. Prednacinolone
3. Locapred
4. Desowen
5. Desonate
6. Topifug
7. Desonida
8. Desonidum
9. Tridesilon
10. Apolar
11. Verdeso
12. D-2083
13. Steroderm
14. Sterax
15. Desfluorotriamcinolone Acetonide
16. 16alpha-hydroxyprednisole-16,17-acetonide
17. Tridesonit
18. D2083
19. Desilux
20. 16alpha,17alpha-isopropylidenedioxyprednisolone
21. Chebi:204734
22. 16alpha-hydroxyprednisolone-16alpha,17-acetonide
23. J280872d1o
24. Nsc-759226
25. Hamiltoderm
26. Flusemidon
27. Reticus
28. Zotinar
29. 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
30. 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
31. 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
32. Dsstox_cid_26756
33. Dsstox_rid_81880
34. Dsstox_gsid_46756
35. (1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
36. D 2083
37. Desonidum [inn-latin]
38. Desonida [inn-spanish]
39. Desonide [usan:inn:ban]
40. Cas-638-94-8
41. Desowen (tn)
42. Verdeso (tn)
43. Mfcd00866151
44. 16-alpha-hydroxyprednisole-16,17-acetonide
45. Unii-j280872d1o
46. Ncgc00167983-01
47. Ncgc00274065-01
48. Einecs 211-351-6
49. Desonide (usp/inn)
50. Desonide [usan]
51. Desonide [inn]
52. Desonide [mi]
53. Desonide [vandf]
54. Desonide [mart.]
55. Desonide [usp-rs]
56. Desonide [who-dd]
57. Schembl3631
58. 11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Acetone
59. Desonide [orange Book]
60. Gtpl7066
61. Desonide [usp Impurity]
62. Chembl1201109
63. Desonide [usp Monograph]
64. Dtxsid7046756
65. Hms3715p20
66. 11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Acetone
67. Bcp04201
68. Hy-b0248
69. Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11.beta.,16.alpha.)-
70. Tridesilon Component Desonide
71. Zinc4212851
72. Tox21_112603
73. 16alpha-hydroxyprednisolone Acetonide
74. S1701
75. Akos037643323
76. Tox21_112603_1
77. Ccg-221279
78. Db01260
79. Desonide Component Of Tridesilon
80. Nsc 759226
81. (4ar,4bs,5s,6as,6bs,9ar,10as,10bs)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2h-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
82. As-13892
83. Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-
84. Budesonide Impurity F [ep Impurity]
85. D5578
86. D03696
87. F20496
88. Ab01274712-01
89. Ab01274712_02
90. 638d948
91. Prednisolone-16,17-acetonide, 16-alpha-hydroxy-
92. Q904011
93. Q-101382
94. Brd-k21528677-001-03-6
95. 16?,17-[1-methylethylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione
96. (11beta,16alpha)-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna -1,4-diene-3,20-dione
97. (1s,2s,4r,8s,9s,11s,12s,13r)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
98. 16alpha,17-[1-methylethylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4-diene-3,20-dione (desonide)
| Molecular Weight | 416.5 g/mol |
|---|---|
| Molecular Formula | C24H32O6 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Exact Mass | 416.21988874 g/mol |
| Monoisotopic Mass | 416.21988874 g/mol |
| Topological Polar Surface Area | 93.1 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 873 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 8 | |
|---|---|
| Drug Name | Desonate |
| PubMed Health | Desonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | Desonate contains desonide [(pregna-1, 4-diene-3, 20-dione,11, 21-dihydroxy-16, 17-[(1-methylethylidene) bis(oxy)]-,(11,16)]- a synthetic nonfluorinated corticosteroid for topical dermatologic use. Chemically, desonide is C24H32O6. It has the fol... |
| Active Ingredient | Desonide |
| Dosage Form | Gel |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Bayer Hlthcare |
| 2 of 8 | |
|---|---|
| Drug Name | Desonide |
| Drug Label | VERDESO Foam is a white to off-white petrolatum-based emulsion aerosol foam containing the active ingredient desonide, a low-potency topical corticosteroid.Chemically, desonide is (11,16)-11,21-dihydroxy-16,17-[(1-methylethylidene)-bis(oxy)]-pregna-1... |
| Active Ingredient | Desonide |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Fougera Pharms; Perrigo New York; Taro |
| 3 of 8 | |
|---|---|
| Drug Name | Desowen |
| Drug Label | DesOwen Cream 0.05%, Ointment 0.05%, and Lotion 0.05% contain desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17 [(1methylethylidene) bis(oxy)]-,(11,16)- a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corti... |
| Active Ingredient | Desonide |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Galderma Labs |
| 4 of 8 | |
|---|---|
| Drug Name | Verdeso |
| PubMed Health | Desonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | VERDESO Foam is a white to off-white petrolatum-based emulsion aerosol foam containing the active ingredient desonide, a low-potency topical corticosteroid.Chemically, desonide is (11,16)-11,21-dihydroxy-16,17-[(1-methylethylidene)-bis(oxy)]-pregna-1... |
| Active Ingredient | Desonide |
| Dosage Form | Aerosol, foam |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Aqua Pharms |
| 5 of 8 | |
|---|---|
| Drug Name | Desonate |
| PubMed Health | Desonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | Desonate contains desonide [(pregna-1, 4-diene-3, 20-dione,11, 21-dihydroxy-16, 17-[(1-methylethylidene) bis(oxy)]-,(11,16)]- a synthetic nonfluorinated corticosteroid for topical dermatologic use. Chemically, desonide is C24H32O6. It has the fol... |
| Active Ingredient | Desonide |
| Dosage Form | Gel |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Bayer Hlthcare |
| 6 of 8 | |
|---|---|
| Drug Name | Desonide |
| Drug Label | VERDESO Foam is a white to off-white petrolatum-based emulsion aerosol foam containing the active ingredient desonide, a low-potency topical corticosteroid.Chemically, desonide is (11,16)-11,21-dihydroxy-16,17-[(1-methylethylidene)-bis(oxy)]-pregna-1... |
| Active Ingredient | Desonide |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Fougera Pharms; Perrigo New York; Taro |
| 7 of 8 | |
|---|---|
| Drug Name | Desowen |
| Drug Label | DesOwen Cream 0.05%, Ointment 0.05%, and Lotion 0.05% contain desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17 [(1methylethylidene) bis(oxy)]-,(11,16)- a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corti... |
| Active Ingredient | Desonide |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Galderma Labs |
| 8 of 8 | |
|---|---|
| Drug Name | Verdeso |
| PubMed Health | Desonide (On the skin) |
| Drug Classes | Corticosteroid, Strong |
| Drug Label | VERDESO Foam is a white to off-white petrolatum-based emulsion aerosol foam containing the active ingredient desonide, a low-potency topical corticosteroid.Chemically, desonide is (11,16)-11,21-dihydroxy-16,17-[(1-methylethylidene)-bis(oxy)]-pregna-1... |
| Active Ingredient | Desonide |
| Dosage Form | Aerosol, foam |
| Route | Topical |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Aqua Pharms |
For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.
Desonide is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
D07AB08
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AB - Corticosteroids, moderately potent (group ii)
D07AB08 - Desonide
S - Sensory organs
S01 - Ophthalmologicals
S01B - Antiinflammatory agents
S01BA - Corticosteroids, plain
S01BA11 - Desonide
Absorption
Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
API SUPPLIERS
Axplora is your partner of choice for complex APIs.
Click Us!
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-09-05
Pay. Date : 2014-09-03
DMF Number : 19574
Submission : 2006-07-06
Status : Active
Type : II
NDC Package Code : 46439-8713
Start Marketing Date : 1992-03-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : EU, CN |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22963
Submission : 2009-07-20
Status : Active
Type : II
Date of Issue : 2022-08-24
Valid Till : 2025-07-29
Written Confirmation Number : WC-0099
Address of the Firm :
NDC Package Code : 15308-0713
Start Marketing Date : 1983-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF |
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-01-17
Pay. Date : 2014-01-14
DMF Number : 4420
Submission : 1982-02-03
Status : Active
Type : II
| Available Reg Filing : CA, ASMF |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1244
Submission : 1968-10-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4008
Submission : 1980-12-05
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5476
Submission : 1984-07-05
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22749
Submission : 2009-04-21
Status : Inactive
Type : II
NDC Package Code : 24002-0014
Start Marketing Date : 2009-08-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3100
Submission : 1978-01-03
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CREAM;TOPICAL - 0.05%
USFDA APPLICATION NUMBER - 17010
DOSAGE - OINTMENT;TOPICAL - 0.05%
USFDA APPLICATION NUMBER - 17426
DOSAGE - GEL;TOPICAL - 0.05% **Federal Regist...DOSAGE - GEL;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 21844
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Thickeners and Stabilizers
Solubilizers
Emulsifying Agents
Film Formers & Plasticizers
Surfactant & Foaming Agents
Coating Systems & Additives
Parenteral
Lubricants & Glidants
Granulation
Fillers, Diluents & Binders
Direct Compression
Taste Masking
Controlled & Modified Release
API Stability Enhancers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
67
PharmaCompass offers a list of Desonide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Desonide manufacturer or Desonide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Desonide manufacturer or Desonide supplier.
PharmaCompass also assists you with knowing the Desonide API Price utilized in the formulation of products. Desonide API Price is not always fixed or binding as the Desonide Price is obtained through a variety of data sources. The Desonide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Desonide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Desonide, including repackagers and relabelers. The FDA regulates Desonide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Desonide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Desonide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Desonide supplier is an individual or a company that provides Desonide active pharmaceutical ingredient (API) or Desonide finished formulations upon request. The Desonide suppliers may include Desonide API manufacturers, exporters, distributors and traders.
click here to find a list of Desonide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Desonide DMF (Drug Master File) is a document detailing the whole manufacturing process of Desonide active pharmaceutical ingredient (API) in detail. Different forms of Desonide DMFs exist exist since differing nations have different regulations, such as Desonide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Desonide DMF submitted to regulatory agencies in the US is known as a USDMF. Desonide USDMF includes data on Desonide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Desonide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Desonide suppliers with USDMF on PharmaCompass.
A Desonide written confirmation (Desonide WC) is an official document issued by a regulatory agency to a Desonide manufacturer, verifying that the manufacturing facility of a Desonide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Desonide APIs or Desonide finished pharmaceutical products to another nation, regulatory agencies frequently require a Desonide WC (written confirmation) as part of the regulatory process.
click here to find a list of Desonide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Desonide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Desonide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Desonide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Desonide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Desonide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Desonide suppliers with NDC on PharmaCompass.
Desonide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Desonide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Desonide GMP manufacturer or Desonide GMP API supplier for your needs.
A Desonide CoA (Certificate of Analysis) is a formal document that attests to Desonide's compliance with Desonide specifications and serves as a tool for batch-level quality control.
Desonide CoA mostly includes findings from lab analyses of a specific batch. For each Desonide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Desonide may be tested according to a variety of international standards, such as European Pharmacopoeia (Desonide EP), Desonide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Desonide USP).
